

AD _____

Award Number: W81XWH-04-1-0474

TITLE: Functional Genomic Analysis of Breast Cancer Cell Tumorigenicity Using a
Novel Gene Silencing Resource

PRINCIPAL INVESTIGATOR: Douglas S. Conklin, Ph.D.

CONTRACTING ORGANIZATION: The Research Foundation
State University of New York
Albany NY 12201-0009

REPORT DATE: April 2007

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the
author(s) and should not be construed as an official Department of the Army
position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE (DD-MM-YYYY) 01-04-2007		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 31 Mar 06 – 30 Mar 07	
4. TITLE AND SUBTITLE Functional Genomic Analysis of Breast Cancer Cell Tumorigenicity Using a Noval Gene Silencing Resource				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-04-1-0474	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Douglas S. Conklin, Ph.D. E-Mail: dconklin@albany.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The Research Foundation State University of New York Albany NY 12201-0009				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT We have identified approximately 30 genes that negatively impact the growth of Erb-B2 positive breast cancer cells. Year 2 of funding resulted in tests of the specificity of the shRNAs' negative impact on the growth of Erb-B2 positive breast cancer cells. Effects of these shRNAs on normal cells and other breast cancer cell lines, identified approximately 20 shRNAs that specifically inhibit Erb-B2 positive breast cancer cells target genes. Several of these gene targets are known to be important to a variety of cancers. The PBP and NR1D1 genes are interesting because they give new insight into a pathway that can be exploited as a potential therapeutic target. Year 3 of funding resulted in finding that inhibition of PBP-PPAR γ -NR1D1 does not affect ERBB2 signaling in breast cancer cells. That this pathway is overactive in her-2/neu breast cancer cells is likely due to the tight genetic linkage of Nr1D1 and her-2. We have also found that the PBP-PPAR γ -NR1D1 pathway alters fat metabolism in breast cancer cells and have identified lipotoxicity as a likely mechanism for triggering apoptosis in the her-2/neu positive breast cancer cells.					
15. SUBJECT TERMS FUNCTIONAL GENOMICS, CELL SIGNALING, GENE THERAPY, RNAI					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			USAMRMC
			UU	19	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Introduction.....	4
Body.....	5
Key Research Accomplishments.....	14
Reportable Outcomes.....	15
Conclusions.....	17
References.....	18
Appendices.....	N/A

Introduction

The recent explosion of genome sequences and bioinformatic data has changed the nature of mammalian genetics. Systematic investigation of expression patterns of thousands of genes in breast tumors using cDNA microarrays and serial analysis of gene expression has yielded a long list of genes whose increased activity is correlated with the occurrence of breast cancer (1-4). In notable cases, associations between gene expression levels and clinical outcome have been determined. In most cases, however, the information is only correlative and serves as a rough guide to genes that might positively influence some aspect of breast cancer.

We are working towards identifying which of the nearly 100 genes typically overexpressed in ErbB-2 positive breast tumors are important for the survival and aggressiveness of breast cancer cells. Our approach makes use of DNA-encoded short hairpin RNAs that elicit an RNA interference silencing of the overexpressed genes. Using high throughput methodologies, we have constructed a library of sequence-verified hairpins that target most human genes (5). Constructs from the library have been used for the systematic validation of breast cancer molecular profiling data in ErbB-2 positive BT 474 cells. The overall objective of this proposal is to identify hairpins that have inhibitory effects on breast cancer progression in *in vivo* models as this would add to our understanding of the genes involved in breast cancer and identify their products as potential small molecule therapeutic targets. It would also pave the way for testing of the hairpins that we identify as gene therapeutics.


The underlying hypothesis of this proposal is that functional genomic screening with DNA-encoded RNA interference can identify those genes that breast cancer cells actually rely on to cause cancer. We will systematically target the most commonly overexpressed genes in breast cancer cells especially those that are overexpressed in association with ErbB-2 amplification. Many of these genes are likely to be involved in granting some sort of survival advantage to these cells during cancer progression. Silencing key genes in this group should reverse the cancer phenotype. In this way, we expect to gain insights into which genes are actually required by breast cancer cells to cause cancer and would therefore make excellent therapeutic targets. Moreover, it may contribute directly to the development of gene-based therapeutics by identifying short hairpin RNAs that could someday be used clinically.

Body

An RNAi screen targeting genes overexpressed in ERBB2-positive breast cancer

Since ERBB2-positive breast cancer patients with metastatic disease show overall Herceptin response rates of between ~10 and 25%, it is likely that factors other than ERBB2 itself must affect the aggressiveness and poor therapy response in these tumors. So that genes required for the survival of ERBB2 breast cancer cells could be identified, we performed a functional RNAi screen of 144 genes previously identified by expression profiling meta-analyses to be upregulated in ERBB2-positive breast cancer¹⁻⁶. A total of 323 short-hairpin RNAs (shRNAs) expressed from the pSHAG-MAGIC 2 (pSM2)

vector were used to down regulate or “knock down” the expression of these genes in the well-characterized, ERBB2-positive BT474 breast cancer cell line. To monitor the effects of shRNAs on the cells, we used alamarBlue, a colorimetric indicator of cell viability (**Fig. 2A**). Eleven shRNAs resulted in more than a 50% decrease in cell viability (**Fig. 2B**). This group contained an ERBB2 shRNA that caused the largest decrease in alamarBlue staining (~70%). This was expected since the role of ERBB2 in breast cancer cell proliferation is well established⁷. Other genes which when knocked down produced more than a 50% decrease in cell viability included genes with known roles in cancer cell proliferation. These included CA9⁸, BNIP3L⁹, KI67, and TPD52 (**Fig. 2B**). Knockdown of ERBB3, another member of the EGFR family that heterodimerizes with ERBB2 as its preferred partner⁷, also had a modest impact on cell viability, resulting in ~31% of alamarBlue decrease (data not shown). That the screen identified these genes known to be important to breast cancer cell proliferation validates the utility of this approach in identifying genes important for the survival of this type of cancer.



Surprisingly, three of the shRNAs that had the most dramatic effect, targeted genes that had been shown previously to play roles in adipogenesis. These included PPAR γ binding protein (PBP)¹⁰, nuclear receptor subfamily 1, group D, member 1 (NR1D1 or RevErb α)¹¹, and the MAP kinase, MAP2K6¹². Two others, fatty acid desaturase 2 (FADS2)¹³ and STARD3¹⁴, which had less of an effect, also are involved in this process. PBP and NR1D1 are particularly interesting. They are genetically linked, both residing on the 17q12-21 amplicon, together with ERBB2 (Fig. 3). They are also functionally linked; a number of studies have shown them to be required for transcriptional regulation of lipid metabolism and adipocyte differentiation. PBP is a co-activator of PPAR γ . PPAR γ has been extensively studied and positively regulates adipogenic genes including NR1D1. NR1D1, which is an orphan nuclear receptor, is relatively poorly understood but is thought to normally act as a negative regulator of transcription. It may act by inhibiting expression of anti-adipogenic genes¹⁵ or upregulating genes such as PPAR γ (11 and Fig. 3).

Although we would have liked to carry out studies of the effect of each shRNA on a more extensive panel of breast cancer cell types, we were able to gain some idea of the specificity of effect for the ERBB2, PBP and NR1D1 shRNAs. The best 15 shRNA hits from the initial screen were transfected into other breast cancer cell lines including the MDA-MB-361 (ERBB2-positive), MCF-7 (ERBB2-negative), normal human mammary epithelial cells (HMECs) a non-breast derived tumorigenic cell line, HEK 293FT cells and BT474s(ERBB2-positive, ER). Cells were assayed using the same approach as in the original screen. The ERBB2 shRNA specifically had an impact on the two ERBB2-positive breast cancer cell lines, BT474 and MDA-MB-361 (Fig. 4), as expected. Interestingly, the NR1D1 shRNA resulted in decreased viability of the same two cell lines yet was without effect on MCF7s and HMECs (Fig. 4). PBP inhibited BT474 proliferation but had no effect on MDA-MB-361 cells. This may be due to higher levels of PBP dosage in these cells which also possess the 17q12-21 amplicon. We have confirmed the gene silencing activity of the PBP and NR1D1 shRNAs both at the message and the protein levels. Both shRNAs decrease levels of mRNA approximately 60% and since the abundance of mRNAs from closely linked genes does not change we are confident that these shRNAs act at the post-transcriptional level. siRNAs to NR1D1 have also been tested yet have less of an effect (data not shown).





Figure 4. Screen hits tested for effects on other cell lines. An ERBB2-positive cell line (MDA-MB-361), a non-ERBB2 overexpressing cell line (MCF-7), normal mammary epithelial cells (HMEC) and a non-breast cell line (HEK 293) were transfected with shRNAs. Experiments were performed as in Fig.1. Error bars represent standard deviations from triplicate experiments.




mRNA approximately 60% and since the abundance of mRNAs from closely linked genes does not change we are confident that these shRNAs act at the post-transcriptional level. siRNAs to NR1D1 have also been tested yet have less of an effect (data not shown).

NR1D1 links the circadian clock and metabolism

Although originally linked to regulation of adipocyte differentiation and lipid metabolism^{16, 17}, NR1D1 has been recently identified as a major component of the circadian clock^{18, 19} which coordinates animal behavior and physiology with an approximately 24 hr cycle. Deregulation of circadian rhythms has been associated with jet lag, sleep disorders, metabolic disruptions and tumorigenesis. This system is centrally controlled by the suprachiasmatic nucleus (SCN),

which influences the activity of peripheral clocks through the nervous system. At the molecular level, the circadian clock is maintained by a complex system of feedback loops involving a number of transcription factors. As shown in **Figure 5**, NR1D1 has effects on circadian regulation through its suppression of BMAL1 (Brain and Muscle Arnt-like protein 1) via recruitment of the NCoR/HDAC3 deacetylase²⁰. BMAL1 heterodimerizes with another circadian component, CLOCK (Circadian Locomotor Output Cycles Kaput protein). BMAL1-CLOCK heterodimers can induce expression of NR1D1¹⁹ as well as of another set of clock genes, the PER1 (period homolog 1) and 2 and CRY1 (cryptochrome 1) and 2 genes, thereby forming the positive limb of the circadian clock.



BMAL1 was also found to promote adipocyte differentiation²¹, further supporting the notion of a direct relationship between circadian clock and metabolism. The PER and CRY proteins heterodimerize to inhibit BMAL1-CLOCK mediated transcription, thus acting as a negative circadian component²². DNA binding of BMAL1-CLOCK is strongly enhanced by low NAD/NADH ratio, implying for one more link between circadian rhythm and metabolism²³. **Because of its regulation of fat storage, NR1D1 has been proposed as a potential link between the circadian clock and cellular metabolism²⁴.**

It is of note that a number of studies have shown that disruption of the circadian cycle accelerates malignant growth²⁵⁻²⁷, though the molecular mechanisms remain essentially unknown. Although there has been no direct evidence showing how NR1D1 overexpression could influence breast cancer aggressiveness, this gene has been proposed as a potential druggable target for breast cancer therapy²⁸. Interestingly, the PER family of genes was found to be methylated in a set of breast tumors where ERBB2 was overexpressed²⁹. NR1D1 overexpression and PER methylation in ERBB2-positive tumors may be a consequence of their functional relationship, since NR1D1 suppresses BMAL1 and therefore PER1 expression.


PBP and NR1D1 knockdown results in increased apoptosis in BT474 cells

Since reduced proliferation can result from slowed growth, quiescence or increased cell death, the cause of the decreased proliferation of ERBB2-positive cells due to PBP and NR1D1 knockdown was determined. Cells were transfected with PBP, NR1D1, ERBB2 and Luciferase shRNAs. GFP was used as a marker of transfection. Cells were monitored for three days and imaged using a InCell high-content imaging system (General Electric), in order to quantify the number of transfected cells based on GFP expression (data not shown). Results showed a time dependent decrease in the number of cells transfected with the NR1D1 shRNA. A similar though smaller effect was observed with the PBP-transfected cells. That transfected cells were lost from the population implied that cell death was responsible for the decrease in alamarBlue signal seen in the primary screen. ERBB2 knockdown did not have the same phenotypic effect, since the number of transfected cells did not decrease with time (data not shown) which agrees with some other studies showing that the major effect of ERBB2 knockdown is cytostatic³⁰⁻³². These results, which indicate a difference in the genetic phenotype, imply that PBP and NR1D1 may not function in the same biological pathway as ERBB2, although they all map closely together.


In order to examine whether cell death caused by the PBP and NR1D1 shRNAs is due to apoptosis, we employed detection of activated Bax and cleaved Caspase-3 by immunofluorescence. When active, Bax translocates to mitochondria inducing changes in mitochondrial membrane permeability that enables cytochrome C to be released in the cytoplasm and triggers the Caspase cascade. Caspase-3 is a major component of the apoptotic machinery and is proteolytically cleaved to its active form by a variety of stimuli promoting cell apoptosis. Images of shRNA-transfected cells and digital quantification of the active Bax signal (**Fig. 6A**) showed that cells transfected with the NR1D1 and PBP shRNAs, but not with the ERBB2 shRNA, exhibited increased apoptosis compared to the control. Images of shRNA-transfected cells and digital quantification of the Caspase-3 signal (**Fig. 6B**) showed that cells transfected with the NR1D1 and PBP shRNAs also exhibited increased apoptosis compared to the control. PBP knockdown increased Caspase-3 cleavage 3-fold. This effect was smaller than 5-fold increase caused by the NR1D1 shRNA and is consistent with the observed differences in live cell counts (data not shown). This result could be attributed to either the higher efficiency of the NR1D1 shRNA or to a more central role of NR1D1 in BT474 survival. These results show that NR1D1 and PBP knockdown cause apoptotic cell death in BT474 cells. That NR1D1 shRNA had a more profound effect on cell viability and increased apoptosis, compared to PBP and ERBB2, points to the importance of NR1D1 to BT474 cell viability.


PPAR γ antagonists result in NR1D1 knockdown and apoptosis induction of amplicon-possessing cells

NR1D1 and PBP are both functionally related to PPAR γ . PBP is a co-activator of PPAR γ . NR1D1 is a target of PPAR γ and has been shown to positively regulate PPAR γ expression. PPAR γ transcriptional activity is activated by a number of different fatty acid metabolites. Several agonists and antagonists are available. To determine whether PPAR γ is a mediator of the PBP-NR1D1 pathway in the amplicon-positive breast cancer cells, we treated BT474, MDA-MB-361, MCF-7 and HMEC cells with several concentrations of two antagonists that bind irreversibly to PPAR γ , GW9662 and T0070907 (**Fig. 7A,B**). Although both drugs were toxic to all cells, BT474 and MDA-MB-361 cells were more sensitive to treatment than MCF-7 and HMEC cells (**Fig. 7A,B**). That these cell lines are more sensitive is similar to the effects seen with PBP and NR1D1 shRNAs. GW9662 appeared to affect PPAR γ signaling since treatment resulted in decreased NR1D1 expression, as expected (**Fig. 7C**) and increased apoptosis of BT474 cells, as shown by active Bax (**Fig. 7D**) and cleaved Caspase-3 (**Fig. 7E**). Hence, PPAR γ inhibitors have the same phenotypic effects and the same pattern of specificity as the



PBP and NR1D1 shRNAs, which may occur, at least in part, through the downregulation of NR1D1 and indicate that these three genes function as part of a single pathway that is required for breast cancer cell survival. **We refer to this as the NR1D1 pathway.** That we found that drugs targeting PPAR γ had an effect on cancer cells is not novel. An enormous literature exists on the use of PPAR γ agonists in treating cancer (for review ³³). Fewer studies have been conducted with antagonists. In both cases, there are conflicting results and no unified picture has emerged. Our results are unique since they point to effects of PPAR γ antagonists on cells with a specific genotype. Irrespective of potential therapeutic use these drugs are useful as tools, since they affect the same pathway and do not suffer from issues related to transfection.







Inhibition of PBP-PPAR γ -NR1D1 does not affect ERBB2 signaling

Since shRNAs and PPAR γ antagonists specifically induced apoptosis in ERBB2-positive breast cancer cells, it was necessary to investigate whether ERBB2 signaling is affected by inhibiting the PBP- PPAR γ -NR1D1 pathway. To do this, we examined ERBB2 signaling in BT474 cells after treatment with the PPAR γ antagonist GW9662. Neither ERBB2 expression (**Fig. 8A**), nor ERBB2 phosphorylation on two tyrosine residues that are targets of phosphorylation (**Fig. 8B**) were significantly affected by the GW9662 treatment. It is widely accepted that the two major effectors activated by ERBB2 are the PI3K-Akt and the MAPK pathways. Akt phosphorylation is not altered after treatment with the PPAR γ antagonist (**Fig. 8C**), in agreement with the ERBB2 phosphorylation status. However, a high dose of GW9662 resulted in decreased ERK phosphorylation (**Fig. 8C**), contrary to ERBB2 phosphorylation status. The latter may be a direct effect of PPAR γ inhibition, since it has been shown that PPAR γ positively regulates ERK signaling

(^{34, 35}). Although they are somewhat preliminary, these results indicate that a simple relationship does not exist between the PPAR γ -NR1D1 pathway and ERBB2. Specific Aim 1 is directed at further analyzing potential interactions between ERBB2 and the NR1D1 pathway.





The PBP-PPAR γ -NR1D1 pathway alters fat metabolism in breast cancer cells


PPAR γ and NR1D1 are major regulators of adipogenesis and lipid homeostasis. Up-regulation of these genes promotes lipid accumulation in fat stores during adipocyte differentiation^{11, 15, 16, 36}. Since both genes are likely to have a number of targets, it was important to determine whether this function was relevant to the breast cancer cells. As shown in **Figures 9** and **10**, several lines of evidence indicate that ERBB2-positive breast cancer cells have increased levels of fat. BT474 and MDA-MB-361 cells exhibit strong staining with Oil-Red-O, which stains neutral fat stores, when compared to MCF-7 and HMEC cells (**Fig. 9A**). BODIPY 493/503, a fluorescent probe of cellular lipids gave similar results. (**Fig. 9B**) Quantification of fluorescent signal from BODIPY-stained neutral fats (total granule intensity/cell) was performed by InCell 1000 image capture and quantification with InCell Investigator 3.4 software. ERBB2-positive BT474 and MDA-MB-361 cells showed a 2-fold increase in fat accumulation in lipid stores, when compared to HMEC cells and a 5-fold increase when compared to MCF-7 (**Fig. 9B**). Thin layer chromatography and densitometry confirmed that the neutral fat stores were triglycerides (data not shown).

When quantified by mass spectrometry, differences were also observed in total cellular fats. Since we were primarily interested in learning why the EBRB2-positive cell line was sensitive to treatment with shRNAs and PPAR γ antagonists while the EBRB2-negative cell line was relatively resistant, we focused on differences between these two lines. Total cellular lipids from both were extracted and analyzed by gas chromatography/mass spectrometry³⁷. BT474 cells were found to contain slightly more than twice the amount of total fats when compared to MCF-7 cells (28 nmol/ 10^5 cells versus 13 nmol/ 10^5 cells, data not shown). It is not surprising that BT474s have high total fat content because the gene encoding fatty acid synthase is

overexpressed in these cells³⁸⁻⁴¹. That these cells store the increased fats as triglycerides is somewhat unexpected and may provide a rationale for the requirement of PBP and NR1D1 overexpression in this cell type (see below).

To learn clues about the trigger of apoptosis after inhibition of the PBP-PPAR γ -NR1D1 pathway, we examined cells for changes in the fat metabolic pathway. As shown in **Figure 10B**, inhibition of the PBP-PPAR γ -NR1D1 pathway affected downstream targets involved in lipid metabolism in the breast cancer cells. Expression levels of aP2 (FABP4, fatty acid binding protein 4), one of the most commonly used markers of adipogenesis and of HSL (hormone sensitive lipase) both of which are positively regulated by PPAR γ during adipocyte differentiation, were downregulated upon use of the PPAR γ antagonist GW9662 (**Fig. 10B**). Although the glucose transporter, GLUT4, was also downregulated, we have shown that diminished glucose uptake is not an explanation for apoptosis onset (data not shown). We then examined the effect that inhibition of the pathway would have on fat accumulation. Treatment with a sublethal concentration of PPAR γ antagonist or administration of PBP and NR1D1 shRNA treatment increased fat stores (**Fig. 10C** and data not shown). Levels of several intermediates between palmitate and triglyceride stores also showed modest increases in both BT474 and MCF-7 cells (**Fig. 10D-E**). Although initially surprising, this result is likely due to the downregulation of HSL, a lipase that is responsible for breakdown of triglycerides. **We hypothesize that the major effect of inhibition of the PBP-PPAR γ -NR1D1 pathway is a generalized inhibition of the fat storage processes that are usually coordinated by these transcription factors. That the effect is more profound in ERBB2-positive breast cancer cells reflects the overall higher activity of the fatty acid synthesis pathway in these cells.**


Apoptosis due to PBP-PPAR γ -NR1D1 inhibition is consistent with endogenous palmitate toxicity. The relatively high levels of activity of the fatty acid synthesis pathway in the ERBB2-positive breast cancer cells suggested a possible trigger of apoptosis in these cells. The end-product of FASN activity, palmitate, and other saturated fatty acids like it are toxic to cells, generating a variety of apoptotic signals, including ceramide synthesis⁴² and reactive oxygen species⁴³ (for review see⁴⁴). Studies in a variety of cell types, including breast cancer cell lines^{45, 46} suggest that this lipotoxicity is specific for saturated fatty acids and that exogenous or endogenously generated unsaturated



FASN rescue palmitate-induced apoptosis by promoting palmitate incorporation into triglyceride. In tests, BT474 cells were found to be more sensitive than MCF-7 cells to exogenously added palmitate (**Fig. 11E-F**). The effect on cells was exacerbated by GW9662 (**Fig. 11E-F**) but was largely unaffected by a ceramide synthesis inhibitor (data not shown). These results support the idea that BT474 cells have near toxic levels of endogenously produced palmitate which lead to apoptosis when the triglyceride storage pathway is downregulated.

In the studies in Chinese hamster ovary cells, intracellular palmitate accumulation induces apoptosis through the generation of reactive oxygen species (ROS)⁴³. To test whether PBP-PPAR γ -NR1D1 knockdown resulted in ROS production, we measured ROS by using hydroethidine after BT474 treatment with the PBP and NR1D1 shRNAs (**Fig. 11A-B**) or with the PPAR γ antagonist GW9662 (**Fig. 11C-D**). Results in both cases showed that cells showed increased production of ROS species since both shRNA and antagonist treatments lead to increased fluorescence of hydroethidine. Taken together these results indicate that apoptosis due to PBP-PPAR γ -NR1D1 inhibition is consistent with endogenous palmitate toxicity. Based on our results to date, we hypothesize that increased activity of the PBP-PPAR γ -NR1D1 pathway enables ERBB2 positive breast cancer cells to convert fatty acids to triglycerides, allowing these cells to avert lipotoxicity such that they can continue to catabolize glucose. The tight genetic linkage between NR1D1 and ERBB2, suggests that **ERBB2 positive breast cancer cells are genetically programmed to depend on fatty acid synthesis and triglyceride storage for energy production.**

A working model consistent with our results is shown below (**Fig12**).



Key Research Accomplishments

Year 1.

- Adopted a new vector and shRNA production methodology
- Created a set of encoded hairpins targeted against genes overexpressed in ErbB-2 positive breast tumors
- Developed a relatively rapid and reliable method for quantification of proliferation changes due to shRNA expression in cells
- Identified approximately 30 genes that negatively impact the growth of Erb-B2 positive breast cancer cells

Year 2.

- Tested shRNAs that negatively impact the growth of Erb-B2 positive breast cancer cells for effects on normal cells
- Tested shRNAs that negatively impact the growth of Erb-B2 positive breast cancer cells for effects on other breast cancer cell lines
- Identified approximately 20 shRNAs from the original positives from year 1 that specifically inhibit Erb-B2 positive breast cancer cells target genes. These genes are potential chemotherapeutic targets.
- The PBP and NR1D1 genes are related to adipogenesis. Using small molecule inhibitors and reporter experiments, we have developed a working hypothesis that adipogenic genes may be required for breast cancer proliferation. This is likely to be due to its effect on countering cellular hypoxia.

Year 3.

- **We have examined the relationship of the NR1D1-PBP-PPAR γ pathway to ERBB2 signaling.**
- **We have identified a likely mechanism for triggering apoptosis in the her-2/neu positive breast cancer cells.**
- **We have sought funding for the continuation of this work.**
- **We have prepared a manuscript that will be submitted presently on his work.**

Year 3 Reportable Outcomes

Manuscripts:

Evans, S. S. Markham, A. Torres, A. Kourtidis, and D. Conklin. 2006. An improved minimum description length learning algorithm for nucleotide sequence analysis. *Signals, Systems and Computers*, Oct.-Nov. 2006. 1843-1850

Kourtidis, A., Eiffert, C., and Conklin, D.S., 2006 RNAi Applications in Target Validation. *Ernst Schering Res Found Workshop Systems Biology*. 2007;(61):1-21

Evans, S., A. Kourtidis, T. S. Markham, J. Miller, D. Conklin and A. Torres., 2007, microRNA target detection and analysis for genes related to breast cancer using MDLcompress. *EURASIP Journal on Bioinformatics and Systems Biology*. Volume 2007 (2007), Article ID 43670

Begley, U., M. Dyavaiah, A. Patil, J. P. Rooney, D. DiRenzo, C.M. Young, D.S. Conklin, R.S. Zitomer and T.J. Begley 2007. Trm9 Catalyzed tRNA Modifications Link Translation to the DNA Damage Response. *Mol. Cell (in press)*

Lastro, M.L., Kourtidis, A. Farley, K. and Conklin, D.S. 2007. xCT expression reduces the early cell cycle requirement for calcium. *Cell. Signal. (in press)*

Ranganathan, A.C., A. Kourtidis, S. Ojha, A. Kourtidis, D. S. Conklin and J. A. Aguirre-Ghiso. , 2007, Inducible activation of PERK reveals an intensity-dependent tumor growth inhibitory function. (*submitted*)

Adam, A.P., A. George, B.V. Iglesias, A. Kourtidis, D. S. Conklin and J. A. Aguirre-Ghiso. (2007) Regulation by p38^{SAPK} of a transcription factor network required for tumor cell quiescence. (*in preparation*)

A. Kourtidis, R.D. Carkner, M.J. Brosnan and D.S. Conklin, 2007, An RNAi screen identifies adipogenesis as a survival pathway for breast cancer cells with the *HER2/neu* amplicon. (*in preparation*)

Presentations:

Petunias hold the keys to new cancer research and therapies (invited presentation) American Cancer Society "Wellness Day" May 2007

Functional genomics in mammalian cells (invited presentation), University of Pittsburgh Cancer Center, February 2007

Development of cell lines, tissue or serum repositories:

As was proposed, the collection of shRNA constructs targeting overexpressed genes that contribute to breast cancer tumorigenicity will undoubtedly be useful to many investigators and will be made available as soon as testing is complete.

Funding applied for based on work supported by this award:

Submission of an RO1 is planned for February 2008 with preliminary results produced from this project.

Additionally, the following proposals made possible by this award have been submitted:

American Cancer Society (Conklin) \$850,000 total
"NR1D1 Pathway in Breast Cancer"

The major goal of this project is to determine the role that this pathway plays in breast cancer.

Role: **Principal Investigator**

Employment or research opportunities applied for and/or received based on experience/training supported by this award:

None in this year.

Year 3 Conclusions

Year 1 of funding resulted in the collation of a large set of constructs targeting genes overexpressed in ErbB-2 positive breast tumors. We have also developed a relatively rapid and reliable method for quantification of proliferation changes due to shRNA expression in cells. Using this we have identified approximately 30 genes that negatively impact the growth of Erb-B2 positive breast cancer cells.

Year 2 of funding resulted in tests of the specificity of the shRNAs' negative impact on the growth of Erb-B2 positive breast cancer cells. Effects of these shRNAs on normal cells and other breast cancer cell lines, identified approximately 20 shRNAs that *specifically* inhibit Erb-B2 positive breast cancer cells target genes. Several of these gene targets are known to be important to a variety of cancers. The PBP and NR1D1 genes are interesting because they give new insight into a pathway that can be exploited as a potential therapeutic target.

Year 3 of funding resulted in finding that inhibition of PBP-PPAR γ -NR1D1 does not affect ERBB2 signaling in breast cancer cells. That this pathway is overactive in her-2/neu breast cancer cells is likely due to the tight genetic linkage of Nr1D1 and her-2. We have also found that the PBP-PPAR γ -NR1D1 pathway alters fat metabolism in breast cancer cells and have identified lipotoxicity as a likely mechanism for triggering apoptosis in the her-2/neu positive breast cancer cells.

“So what?” one might ask.

Our unbiased approach has identified the PBP and NR1D1 genes, which are related to adipogenesis, as genes required by Erb-B2 positive breast cancer for survival. Using small molecule inhibitors and reporter experiments, we have developed a working hypothesis that adipogenic genes may be required for breast cancer proliferation. Further work has led to a working hypothesis in which amplification of genes from the 17q12-21 chromosomal region supercharge fatty acid production. ERBB2 upregulates FAS. PBP and NR1D1 function in conjunction with PPAR α to increase storage of triglycerides and allow for continued glycolysis. Inhibition of PBP, PPAR α or NR1D1 which positively influence several steps in fat production and storage, leads to palmitate accumulation and lipotoxicity resulting in apoptosis.

These genes and the pathway that they operate in are potential chemotherapeutic targets. Our ability to inhibit Erb-B2 positive breast cancer cell proliferation *in vitro* with a small molecule inhibitor of this pathway underscores the potential of this approach.

References

1. Bertucci, F., Goncalves, A. & Maraninchi, D. [Therapeutic implications of advances in breast cancer biology]. *Rev Prat* 54, 865-70 (2004).
2. Kauraniemi, P., Barlund, M., Monni, O. & Kallioniemi, A. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. *Cancer Res* 61, 8235-40 (2001).
3. Kauraniemi, P. et al. Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines. *Oncogene* 23, 1010-3 (2004).
4. Kauraniemi, P., Kuukasjarvi, T., Sauter, G. & Kallioniemi, A. Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. *Am J Pathol* 163, 1979-84 (2003).
5. Mackay, A. et al. cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. *Oncogene* 22, 2680-8 (2003).
6. Perou, C. M. et al. Molecular portraits of human breast tumours. *Nature* 406, 747-52 (2000).
7. Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. *Nat Rev Mol Cell Biol* 2, 127-37 (2001).
8. Bartosova, M. et al. Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2. *J Pathol* 197, 314-21 (2002).
9. Mellor, H. R. & Harris, A. L. The role of the hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer. *Cancer Metastasis Rev* (2007).
10. Zhu, Y. et al. Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR. *J Biol Chem* 275, 13510-6 (2000).
11. Fontaine, C. et al. The orphan nuclear receptor Rev-Erbalpha is a peroxisome proliferator-activated receptor (PPAR) gamma target gene and promotes PPARgamma-induced adipocyte differentiation. *J Biol Chem* 278, 37672-80 (2003).
12. Engelman, J. A. et al. Constitutively active mitogen-activated protein kinase kinase 6 (MKK6) or salicylate induces spontaneous 3T3-L1 adipogenesis. *J Biol Chem* 274, 35630-8 (1999).
13. Cho, H. P., Nakamura, M. & Clarke, S. D. Cloning, expression, and fatty acid regulation of the human delta-5 desaturase. *J Biol Chem* 274, 37335-9 (1999).
14. Watari, H. et al. MLN64 contains a domain with homology to the steroidogenic acute regulatory protein (StAR) that stimulates steroidogenesis. *Proc Natl Acad Sci U S A* 94, 8462-7 (1997).
15. Laitinen, S., Fontaine, C., Fruchart, J. C. & Staels, B. The role of the orphan nuclear receptor Rev-Erb alpha in adipocyte differentiation and function. *Biochimie* 87, 21-5 (2005).
16. Chawla, A. & Lazar, M. A. Induction of Rev-ErbA alpha, an orphan receptor encoded on the opposite strand of the alpha-thyroid hormone receptor gene, during adipocyte differentiation. *J Biol Chem* 268, 16265-9 (1993).
17. Kassam, A., Capone, J. P. & Rachubinski, R. A. Orphan nuclear hormone receptor RevErbalpha modulates expression from the promoter of the hydratase-dehydrogenase gene by inhibiting peroxisome proliferator-activated receptor alpha-dependent transactivation. *J Biol Chem* 274, 22895-900 (1999).
18. Preitner, N. et al. The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. *Cell* 110, 251-60 (2002).
19. Triqueneaux, G. et al. The orphan receptor Rev-erbalpha gene is a target of the circadian clock pacemaker. *J Mol Endocrinol* 33, 585-608 (2004).
20. Yin, L. & Lazar, M. A. The orphan nuclear receptor Rev-erbalpha recruits the N-CoR/histone deacetylase 3 corepressor to regulate the circadian Bmal1 gene. *Mol Endocrinol* 19, 1452-9 (2005).
21. Shimba, S. et al. Brain and muscle Arnt-like protein-1 (BMAL1), a component of the molecular clock, regulates adipogenesis. *Proc Natl Acad Sci U S A* 102, 12071-6 (2005).
22. Kume, K. et al. mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop. *Cell* 98, 193-205 (1999).
23. Rutter, J., Reick, M., Wu, L. C. & McKnight, S. L. Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. *Science* 293, 510-4 (2001).
24. Ramakrishnan, S. N. & Muscat, G. E. The orphan Rev-erb nuclear receptors: a link between metabolism, circadian rhythm and inflammation? *Nucl Recept Signal* 4, e009 (2006).
25. Davis, S. & Mirick, D. K. Circadian disruption, shift work and the risk of cancer: a summary of the evidence and studies in Seattle. *Cancer Causes Control* 17, 539-45 (2006).
26. Filipski, E. et al. Effects of light and food schedules on liver and tumor molecular clocks in mice. *J Natl Cancer Inst* 97, 507-17 (2005).
27. Filipski, E., Li, X. M. & Levi, F. Disruption of circadian coordination and malignant growth. *Cancer Causes Control* 17, 509-14 (2006).
28. Chin, K. et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiology. *Cancer Cell* 10, 529-41

- (2006).
29. Chen, S. T. et al. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. *Carcinogenesis* 26, 1241-6 (2005).
 30. Wang, C. X. et al. In vitro and in vivo effects of combination of Trastuzumab (Herceptin) and Tamoxifen in breast cancer. *Breast Cancer Res Treat* 92, 251-63 (2005).
 31. Sergina, N. V. et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. *Nature* 445, 437-41 (2007).
 32. Eddy, S. F., Kane, S. E. & Sonenshein, G. E. Trastuzumab-Resistant HER2-Driven Breast Cancer Cells Are Sensitive to Epigallocatechin-3 Gallate. *Cancer Res* 67, 9018-23 (2007).
 33. Panigrahy, D., Huang, S., Kieran, M. W. & Kaipainen, A. PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. *Cancer Biol Ther* 4, 687-93 (2005).
 34. Lennon, A. M., Ramauge, M., Dessouroux, A. & Pierre, M. MAP kinase cascades are activated in astrocytes and preadipocytes by 15-deoxy-Delta(12-14)-prostaglandin J(2) and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor gamma-independent mechanisms involving reactive oxygenated species. *J Biol Chem* 277, 29681-5 (2002).
 35. Han, S., Rivera, H. N. & Roman, J. Peroxisome proliferator-activated receptor-gamma ligands inhibit alpha5 integrin gene transcription in non-small cell lung carcinoma cells. *Am J Respir Cell Mol Biol* 32, 350-9 (2005).
 36. Chawla, A., Schwarz, E. J., Dimaculangan, D. D. & Lazar, M. A. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. *Endocrinology* 135, 798-800 (1994).
 37. Folch, J., Lees, M. & Sloane Stanley, G. H. A simple method for the isolation and purification of total lipides from animal tissues. *J Biol Chem* 226, 497-509 (1957).
 38. Zhang, D. et al. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. *Mol Cell Proteomics* 4, 1686-96 (2005).
 39. Menendez, J. A. et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. *Proc Natl Acad Sci U S A* 101, 10715-20 (2004).
 40. Silva, S. D. et al. Expression of fatty acid synthase, ErbB2 and Ki-67 in head and neck squamous cell carcinoma. A clinicopathological study. *Oral Oncol* 40, 688-96 (2004).
 41. Sebastiani, V. et al. Tissue microarray analysis of FAS, Bcl-2, Bcl-x, ER, PgR, Hsp60, p53 and Her2-neu in breast carcinoma. *Anticancer Res* 26, 2983-7 (2006).
 42. Shimabukuro, M. et al. Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. *J Biol Chem* 273, 32487-90 (1998).
 43. Listenberger, L. L., Ory, D. S. & Schaffer, J. E. Palmitate-induced apoptosis can occur through a ceramide-independent pathway. *J Biol Chem* 276, 14890-5 (2001).
 44. Schaffer, J. E. Lipotoxicity: when tissues overeat. *Curr Opin Lipidol* 14, 281-7 (2003).
 45. Hardy, S. et al. Saturated fatty acid-induced apoptosis in MDA-MB-231 breast cancer cells. A role for cardiolipin. *J Biol Chem* 278, 31861-70 (2003).
 46. Hardy, S., Langelier, Y. & Prentki, M. Oleate activates phosphatidylinositol 3-kinase and promotes proliferation and reduces apoptosis of MDA-MB-231 breast cancer cells, whereas palmitate has opposite effects. *Cancer Res* 60, 6353-8 (2000).